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Materials
Materials
Materials obtained from commercial suppliers were used without further purification. Polymyxin B and tobramycin were purchased from TCI America. H-Dab(Boc)-OMe was purchased from Chem Impex International. Ficin was purchased from MP Biomedicals.
Deuterated NMR solvents were purchased from Cambridge Isotope Laboratories. Amiloride, sucrose, and genistein were purchased from Sigma-Aldrich. Nystatin and EDTA/Trypsin were purchased from VWR and chlorpromazine was purchased from
Fisher. Steptavidin-PE-Cy5 was purchased from Biolegend. PBS, F-12 media, Versene, streptavidin Cy-5, LysoTracker Green, and Hoescht dye were purchased from Life Technologies. Streptavidin saporin was purchased from Advanced Targeting Systems. 35 mm glass bottom culture dishes were purchased from MatTek. CellTiter-Blue was purchased from Promega. DOPC (1,2-dioleoyl-snglycero-3-phosphocholine), DOPE (1,2-dioleoylsn-glycero-3-phospho-ethanolamine), and cholesterol were purchased from Avanti Polar
Lipids.
Instrumentation
NMR spectra were recorded on a Varian VX 500 MHz spectrometer or a Varian 400 MHz spectrometer. Mass spectra were recorded at UCSD Chemistry and Biochemistry Mass Spectrometry Facility utilizing an Agilent 6230 HR-ESI-TOF mass spectrometer. Reverse-phase HPLC purification (CLIPEUS, C18, 5µm, 10x250 mm, Higgins analytical) and analysis (Eclipse, XDB-C18, 5µm, 4.6x150 mm) were carried out on an Agilent 1200 series instrument or Beckman Coulter System Gold 127P Solvent Module. Flow cytometry studies were performed on a BD FACSCalibur. Confocal laser scanning microscopy was performed using a Nikon A1R inverted fluorescence microscope with z-stepping motor. Particle size, polydispersity, and surface charge of the lipid vesicles were measured by dynamic light scattering on a Zetasizer Nano ZS (model ZEN3600 from Malvern Instruments).
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Scheme S1. Synthesis of Boc protected PMBN and Boc guanidinylated PMBN.
PMBN (1)
PMB (2.0 g, 1.4 mmol) was dissolved in 50 mL of H 2 O. Then 42 mg of dithiothreitrol and 450 mg of ficin (320-500 milk clotting units/mg) were added and the reaction was heated to 37 °C and stirred overnight. When all PMB was consumed and only PMBN was detected by HPLC, the reaction was heated to reflux to denature the enzyme. After cooling, the precipitate was filtered off and the mother liqueur was evaporated under reduced pressure. The product was purified by automated flash chromatography Teledyne Isco Redisep Rf C18 30g gold column using a gradient of 0 -15% ACN (0.1 % TFA) in H 2 O (0.1% TFA), resulting in the TFA salt of 1 as a beige solid (1.5 g, 1.0 mmol, 72% yield 99, 173.33, 173.30, 172.72, 172.68, 171.94, 171.59, 171.39, 168.13, 163.29, 163.01, 162.73, 162.44, 135.41, 128.93, 127.37, 119.73, 117.41, 115.09, 112.77, 66.18, 66.01, 59.44, 58.16, 55.76, 52.85, 51.84, 51.72, 51.67, 51.19, 50.38, 39.04, 36.78, 36.38, 36.33, 36.08, 35.85, 30.51, 29.65, 28.61 41, 175.20, 174.17, 174.05, 173.74, 173.35, 172.71, 158.74, 158.39, 137.42, 130.40, 129.72, 128.06, 80.37, 80.14, 69.45, 67.28, 61.50, 61.09, 58.29, 54.82, 54.08, 52.91, 52.19, 52.07, 51.80, 40.49, 38.03, 37.79, 37.53, 36.75, 34.18, 33.24, 32.81, 32.28, 31.55, 30.81, 28.82, 28.40, 24.78, 23.80, 21.38, 20.82, 19.70 
Compound 2b
In a 10 mL flask was added the TFA salt of PMBN (1, 112 mg, 0.0728 mmol), 2 mL MeOH, 2 mL CH 2 Cl 2 , and NEt 3 (110 mg, 1.09 mmol, 152 µL). Then N,N′-Di-Boc-1H-pyrazole-1-carboxamidine (88 mg, 0.284 mmol) was added and the reaction was stirred for 24 hours. The reaction was evaporated under reduced pressure and CH 2 Cl 2 was added and washed with saturated NaHCO 3 . The organic layer was dried over MgSO 4 , filtered, and evaporated under reduced pressure. The product was isolated by automated flash chromatography (0 -10% MeOH in CH 2 Cl 2 over 22 mins) to afford the product 2b as a white solid (75 mg, 0.039 mmol, 53% yield).
1 H NMR (500 MHz, CD 3 OD) δ 7.34 -7.13 (m, 5H), 4. 60 -4.43 (m, 2H) 13 C NMR (126 MHz, CD 3 OD) δ 175. 02, 173.95, 173.65, 173.50, 172.52, 164.59, 164.47, 157.85, 157.62, 153.99, 153.90, 150.97, 137.71, 130.29, 129.69, 128.03, 84.42, 84.35, 84.28, 84.22, 80.45, 80.41, 69.52, 67.23, 61.94, 61.16, 58.18, 57.47, 54.12, 53.62, 52 .82,
52. 37, 52.29, 51.91, 40.45, 38.86, 38.61, 38.57, 37.82, 37.70, 36.79, 33.39, 32.90, 32.43, 32.35, 31.98, 31.13, 30.78, 30.75, 28.74, 28.71, 28.69, 28.65, 28.35, 25.00, 23.81, 21.52, 20.93, 19. 
Compound 6a
5-hexynoic acid (257 µL, 262 mg, 2.33 mmol), 1.1 mL of DIEA (804 mg, 6.22 mmol), and 8.6 mL DMF (filtered through silica), and HATU (887 mg, 2.33 mmol) were added to a 50 mL round bottom flask and allowed to stir for 10 min to give a yellow solution. Next, HDab(Boc)-OMe·HCl (418 mg, 1.56 mmol) was added and the reaction was stirred overnight. To the reaction was added CH 2 Cl 2 , which was washed with 2% citric acid and then sat. NaHCO 3 . The organic layer was dried, filtered, and evaporated under reduced pressure. The product was isolated by automated flash chromatography (20 -90% EtOAc in hexanes over 15 mins) to afford the product as a viscous oil (467 mg, 1.43 mmol, 92% yield). 05, 172.80, 156.23, 83.42, 79.56, 77.41, 77.16, 76.91, 69.45, 52.77, 49.67, 36.51, 34.96, 33.17, 28.52, 24.12, 17.92 
Compound 6b
In a 25 mL flask was added BDabyne-OMe (6a, 212 mg, 0.629 mmol), CH 2 Cl 2 , triisopropylsilane (57 µL) and trifluoroacetic acid (1 mL). The solution was stirred for one hour and evaporated under reduced pressure. The residue was redissolved in CH 2 Cl 2 (2 mL) and NEt 3 (1 mL). Then N,N′-Di-Boc-1H-pyrazole-1-carboxamidine (403 mg, 1.30 mmol) was added and the reaction was stirred overnight. The reaction was diluted with CH 2 Cl 2 and washed with saturated NaHCO 3 . The organic layer was dried over MgSO 4 , filtered, and evaporated under reduced pressure. The product was isolated by automated flash chromatography (20 -60% EtOAc in hexanes over 19 mins) to afford the product 6b as an oil. 173.71, 164.47, 157.75, 154.01, 84.49, 84.16, 80.50, 70.25, 52.84, 51.54, 38.22, 35.59, 31.73, 28.61, 28.23, 25.77, 18.60 
Compound 8a
BDabyneOMe (6a, 28.5 mg, 0.064 mmol) and Biotin-PEG-N 3 (7, 30.0 mg, .064 mmol) with a 1 mL 3:1:1 mixture of THF, t-BuOH, and H 2 O was were added to a 10 mL round bottom flask and purged with argon for 10 min. Next, 35 µL of a freshly prepared 1M of a sodium ascorbate and then a 28 µL of 7.5% solution of CuSO 4 ·5H 2 O, both prepared in degassed water, were added. The reaction was stirred overnight. The reaction was evaporated under reduced pressure. The product was isolated by automated flash chromatography (2 -17% MeOH in CH 2 Cl 2 over 18 mins) to afford the product as a white solid (49.8 mg, 0.080 mmol, 85% yield).
1 H NMR (500 MHz, CDCl 3 ) δ 7.57 (s, 1H), 7.43 (d, J = 7.9 Hz, 1NH), 6.94 (brs, 1NH), 6.27 (brd, J = 22.5 Hz, 1NH), 5.40 (brd, J = 23.1 Hz, 1NH), 173.52, 173.50, 163.87, 156.21, 147.29, 122.54, 79.49, 70.61, 70.52, 70.49, 70.15, 70.06, 69.64, 61.96, 60.21, 55.73, 52.68, 50.22, 49.86, 40.70, 39.24, 36.78, 35.82, 35.36, 32.54, 28.56, 28.25, 28.17, 25.69, 25.49, 24.86 
Compound 8b
BGuanDabyneOMe (6b, 28.5 mg, 0.064 mmol) and Biotin-PEG-N 3 (30.0 mg, 0.064 mmol) with a 1 mL 3:1:1 mixture of THF, t-BuOH, and H 2 O was added to a 10 mL round bottom flask and purged with argon for 10 min. Next, 35 µL of a freshly prepared 1M of a sodium ascorbate and then a 28 µL of 7.5% solution of CuSO 4 ·5H 2 O, both prepared in degassed water, were added. The reaction was stirred overnight. The reaction was evaporated under reduced pressure. The product was isolated by automated flash chromatography (5 -12% MeOH in CH 2 Cl 2 over 19 mins) to afford the product as a white solid (49.8 mg, 0.080 mmol, 85% yield). 17, 176.08, 175.63, 173.75, 166.09, 164.47, 157.74, 153.99, 124.26, 84.49, 80.49, 71.56, 71.49, 71.43, 71.26, 70.57, 70.41, 63.35, 61.60, 57.03, 52.89, 51.54, 51.34, 41.08, 40.47, 40.34, 38.24, 36.77, 36.72, 35.99, 31.79, 29.78, 29.50, 28.61, 28.23, 26.87, 26.57, 25.68 BDabOMeBiotin (8a, 27 mg, 0.035 mmol), 1.25 mL of MeOH, and 0.42 mL of 0.1 M LiOH solution in water (1 mg, .042 mmol) were added to a 10 mL round bottom flask and stirred overnight. The compound was desalted on a C-18 sep-pak (waters) to provide the product 3a as a white solid (22 mg, 0.029 mmol, 82% yield).
1 H NMR (500 MHz, CD 3 OD) δ 7.87 (s, 1H), 4.57 -4.53 (m, 2H), 4.49 (ddd, J = 7.9, 4.9, 0.7 Hz, 1H), 4.33 -4.27 (m, 2H), 3.91 -3.87 (m, 2H), 3.63 -3.56 (m, 10H), 3.53 (t, J = 5.5 Hz, 2H), 3.35 (t, J = 5.5 Hz, 2H), 3.19 (tt, J = 3.6, 3.2 Hz, 2H), 3.06 -2.98 (m, 1H), 2.92 (dd, J = 12.7, 5.0 Hz, 1H), 2.75 (t, J = 7.6 Hz, 2H), 2.70 (d, J = 12.7 Hz, 1H), 2.32 (t, J = 7.5 Hz, 2H), 2.21 (t, J = 7.4 Hz, 2H), 2.07 -1.94 (m, 4H), 1.78 -1.54 (m, 6H), 1.45 -1.40 (m, 11H).;
13 C NMR (126 MHz, CD 3 OD): δ 176. 17, 176.08, 175.63, 173.75, 166.09, 164.47, 157.74, 153.99, 124.26, 84.49, 80.49, 71.56, 71.49, 71.43, 71.26, 70.57, 70.41, 63.35, 61.60, 57.03, 52.89, 51.54, 51.34, 41.08, 40.47, 40.34, 38.24, 36.77, 36.72, 35.99, 31.79, 29.78, 29.50, 28.61, 28.23, 26.87, 26.57, 25.68 
Compound 3b
BGDabOMeBiotin (8b, 27 mg, 0.035 mmol), 1.25 mL of MeOH, and 0.42 mL of 0.1 M LiOH solution in water (1 mg, .042 mmol) were added to a 10 mL round bottom flask and stirred overnight. The compound was desalted on a C-18 sep-pak (waters) to provide the product 3b as a white solid (22 mg, 0.029 mmol, 82% yield).
1 H NMR (500 MHz, CD 3 OD) δ 7.87 (s, 1H) 
bPMB (10a)
BiotinBDabOH (3a, 20.6 mg, 0.0258 mmol), DIEA (8.6 mg, 0.067 mmol, 11.6 µL), HATU (10.2 mg, 0.027 mmol) and DMF (1 mL) were added to a 10 mL flask and stirred for 10 min. Then Boc-PMBN (2a, 30.4 mg, 0.022 mmol) was added to the reaction and stirred overnight. The reaction was diluted with CH 2 Cl 2 and washed with 5% citric acid and then saturated NaHCO 3 . The organic layer was then dried using MgSO 4 , filtered, and evaporated under reduced pressure. The residue was then taken up in CH 2 Cl 2 /TFA (1:1, 1 mL) containing triisopropylsilane (10 µL) and stirred for 2 hours. The reaction was evaporated under reduced pressure the product was isolated by automated reverse phase flash chromatography using a Teledyne Isco Redisep Rf C18 5.5 g Gold column [5 -30% ACN (0.1% TFA) in H 2 O (0.1% TFA) over 14 mins]. The fractions containing the desired product were lyophilized to provide 4a as a white solid as the TFA salt (19.9 mg, 0.0092 mmol, 48% yield). 69.43, 69.29, 69.26, 68.67, 68.43, 68.39, 66.89, 66.66, 66.08, 61.92, 60.08, 59.32, 58.93, 58.79, 55.62, 55.21, 52.66, 52.57, 51.74, 51.64, 51.55, 51.39, 51.25, 51.05, 50.92, 50.36, 50.24, 39.54, 38.94, 38.74, 36.69, 36.27, 36.19, 36.10, 35.94, 35.80, 35.70, 35.27, 34.22, 30.43, 30.31, 29.59, 29.54, 28.67, 28.48, 28.34, 28.09, 27.71, 27.60, 27.54, 25.00, 24.50, 24.44, 23.52, 23.42, 23.30, 22.18, 20.11, 18.95, 18.73, 18.58, 16.13 
bGPMB (4b)
BiotinBGDabOH (3b, 20.2 mg, 0.0223 mmol), DIEA (12.02 mg, 0.093 mmol, 16.2 µL), PyBrop (10.4 mg, 0.0223 mmol) and DMF (1 mL) were added to a 10 mL flask and stirred for 10 min. Then BocGuan-PMBN (2b, 36.0 mg, 0.0186 mmol) was added to the reaction and stirred overnight. The reaction was diluted with CH 2 Cl 2 and washed with 5% citric acid and then saturated NaHCO 3 . The organic layer was then dried using MgSO 4 , filtered, and evaporated under reduced pressure. The residue was then taken up in CH 2 Cl 2 /TFA (1:1, 1 mL) containing triisopropylsilane (10 µL) and stirred for 2 hours. The reaction was evaporated under reduced pressure the product was isolated by automated reverse phase flash chromatography using a C18 5. , 176.59, 176.38, 175.00, 174.28, 173.96, 173.87, 173.83, 173.38, 173.32, 172.93, 172.63, 172.25, 172.25, 172.00, 171.67, 171.48, 171.43, 165.24, 163.35, 163.07, 162.79, 162.50 (TFA, q, J = 35.7 Hz), 156.77, 156.68, 156.64, 156.54, 147.26, 135.40, 128.91, 127.37, 123.55, 117.43, 115.11 (TFA, q, J = 291.5 Hz), 69.57, 69.52, 69.39, 68.78, 68.72, 66.85, 66.54, 66.06, 62.01, 60.19, 59.48, 59.29, 59.04, 55.86, 55.30, 52.59, 51.95, 51.70, 51.50, 51.18, 50.53, 49.84, 39.64, 39.04, 38.85, 37.83, 37.76, 37.39, 36.77, 35.39, 34.47, 34.38, 30.80, 29.76, 29.19, 27.84, 27.66, 25.10, 24.82, 23.95, 23.47, 22.29, 20.21, 19.09, 18.86, 18.72 
Octaarginine (bArg8)
bArg8 was synthesized using standard solid phase peptide synthesis protocols (Rink amide resin). An aminohexanoic acid (Ahx) spacer was introduced in the N-terminus and biotin-NHS (4 eq) was coupled to the peptide's N-terminus over 1 h at rt in DMF containing DIEA (8 eq). The peptide was cleaved from the resin using TFA/TIS/water (95:2.5:2.5) at rt for 3h. The resin was filtered off and the peptide precipitated by the addition of cold ether and further standing at 4 degrees overnight. Synthesis of alkyne-boc-tobramycin (11a), alkyne-boc-guan-tobramycin (11b) and GTobbiotin (12b) were prepared according to literature procedures. 1
bTob (12a)
Alkyne-Boc-Tob (11a, 25mg, 0.024 mmol) and biotin-PEG-N 3 (16 mg, 0.035 mmol) were dissolved in DMF (500 uL) and treated with 0.2M solution of sodium ascorbate in H 2 O (25 µL) and 0.2M solution of CuSO 4 ·5H 2 O (25 µl). The reaction was stirred overnight at room temperature under argon. The reaction was evaporated under reduced pressure. The crude product was dissolved in CH 2 Cl 2 and washed with aqueous KCN solution, EDTA (0.3 M, pH 8) and brine. The organic layer was then dried using MgSO 4 , filtered and evaporated under reduced pressure. The residue was then dissolved in CH 2 Cl 2 /TFA (1:1, 1 mL) containing triisopropylsilane (10 µL) and stirred for 2 hours. The reaction was evaporated under reduced pressure and the product was purified by HPLC using a semiprep RP-C18 column [5 -30% ACN (0.1% TFA) in H 2 O (0.1% TFA) over 12 min]. The fractions containing the desired product were lyophilized to provide the product as a white solid, (20 mg, 0.013 mmol, 54% yield 165.28, 163.30, 163.02, 162.74, 162.45, 146.91, 123.97, 119.77, 117.44, 115.12, 112.80, 100.86, 94.10, 83.56, 77.32, 74.12, 70.92, 70.31, 69.58, 69.53, 69.40, 69.38, 68.78, 68.60, 68.00, 66.48, 64.32, 62.02, 60.20, 55.30, 54.62, 50.15, 49.72, 48.31, 47.70, 39.74, 39.63, 38.94, 38.86, 35.38, 34.86, 29.25, 27.81, 27.71, 27.64, 25.09, 24.93, 23.78 
PMB (14)
PMB was isolated from the mixture of isomers by HPLC using a RP-C18 
GPMB (15)
MeOH (15 mL) and NEt 3 (239 mg, 2.36 mmol, 329 µL) were added to 14 (226 mg, 0.157 mmol) followed by N,N′-Di-Boc-1H-pyrazole-1-carboxamidine (195 mg, 0.142 mmol) and stirred overnight. The reaction was evaporated under reduced pressure and CH 2 Cl 2 was added and washed with saturated NaHCO 3 . The organic layer was dried over MgSO 4 , filtered, and evaporated under reduced pressure. The residue was then dissolved in CH 2 Cl 2 /TFA (1:1, 4 mL) containing triisopropylsilane (44 µL) and stirred for 2 hours. The reaction was diluted with 5 mL of CH 2 Cl 2 and extracted with 10 mL of H 2 O. The water was evaporated under reduced pressure and the product was isolated by HPLC using a RP-C18 column [5-50% ACN (0.1% TFA) in H 2 O (0.1% TFA) over 40 mins]. The fractions containing the desired product were lyophilized to provide the TFA salt of GPMB as a white solid, (74.7 mg, 0.0378 mmol, 24% yield). 1 H NMR (400 MHz, D 2 O): δ 7. 3H), 7.26 (d, J = 6.9 Hz, 2H), 1H), 4.45 (ddd, J = 17.2, 8.7, 5.3 Hz, 3H), 6H), 2H), 14H) , 2.33 (t, J = 7.2 Hz, Figure S6 . Cellular uptake of saporin. a) Saporin (no streptavidin) was incubated with bPMB or bGPMB for 20 min then dliuted to final saporin concentrations and added to CHO-K1 cells. After four days, the number of viable cells was determined using CellTiterBlue assay and measuring the flourescence intensity at 560/590. b) pgsA cells were incubated with transporter-streptavidin-saporin conjugates at 37 °C. After four days, the number of viable cells was determined using CellTiter-Blue and measuring fluorescence intensity at 560/590 Z-average (± SD) / nm PDI (± SD) Z-potential (± SD) / mV Table S1 . Physicochemical characterization of liposomes. Size, polydispersity, and zeta-potential of evaluated liposomes. Plain liposomes were compared to liposomes mixed with 10 mol% GPMB or 10 mol% PMB. 
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